Pomerantz To Lead Biohaven Investors' FDA Approval Suit
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge...To view the full article, register now.
Already a subscriber? Click here to view full article